Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study

BACKGROUND: Ribociclib plus letrozole demonstrated manageable safety and efficacy profiles in hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2−) advanced breast cancer (ABC) in the Phase 3b CompLEEment-1 trial. OBJECTIVE: To evaluate the safety and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: De Laurentiis, Michelino, Caputo, Roberta, Mazza, Manuelita, Mansutti, Mauro, Masetti, Riccardo, Ballatore, Zelmira, Torrisi, Rosalba, Michelotti, Andrea, Zambelli, Alberto, Ferro, Antonella, Generali, Daniele, Vici, Patrizia, Coltelli, Luigi, Fabi, Alessandra, Marchetti, Paolo, Ballestrero, Alberto, Spazzapan, Simon, Frassoldati, Antonio, Sarobba, Maria Giuseppina, Grasso, Donatella, Zamagni, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684264/
https://www.ncbi.nlm.nih.gov/pubmed/36152144
http://dx.doi.org/10.1007/s11523-022-00913-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684264/
https://www.ncbi.nlm.nih.gov/pubmed/36152144
http://dx.doi.org/10.1007/s11523-022-00913-x

Ejemplares similares